Scientists at the Benaroya Research Institute (BRI) and TrialNet, a global type 1 diabetes (T1D) research consortium, have spent decades working to answer a bold question: Can we stop T1D before it starts?

The FDA recently approved a therapy that marks a huge milestone in preventing T1D. This therapy, teplizumab, can delay T1D for a median of two years.

“Not only is this a landmark event for those with or at risk for T1D, it also shows — for the first time in any autoimmune disease — that it is feasible to treat a disease early, before it starts,” says Carla Greenbaum, MD, director of BRI’s Diabetes Research Program.

Dr. Greenbaum has been a driving force in the research behind this therapy and the clinical trials that tested its safety and effectiveness. She answered some key questions about this new therapy.

Learn more…